Evidence map›Paper›PMID 28525978›Full record

ArticleBMC cancer2017

Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma.

P Bettinsoli, G Ferrari-Toninelli, S A Bonini, C Prandelli, M Memo

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. The Bioactive Gamma-Oryzanol fromAntioxidants (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Targeting Notch in oncology: the path forward.Nature reviews. Drug discovery · 2021
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

P BettinsoliDepartment of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy. paola.bettinsoli@unibs.it.
G Ferrari-ToninelliDepartment of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy.
S A BoniniDepartment of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy.
C PrandelliDepartment of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy.
M MemoDepartment of Molecular and Translational Medicine, University of Brescia Medical School, Viale Europa, 11, Brescia, Italy.
University of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuroblastoma is the most common extracranial solid malignancy in childhood, responsible for 15% of all pediatric cancer deaths. It is an heterogeneous disease that does not always respond to classical therapy; so the identification of new and specific molecular targets to improve existing therapy is needed. We have previously demonstrated the involvement of the Notch pathway in the onset and progression of neuroblastoma. In this study we further investigated the role of Notch signaling and identified Delta-like 1 (DLL1) as a novel molecular target in neuroblastoma cells with a high degree of MYCN amplification, which is a major oncogenic driver in neuroblastoma. The possibility to act on DLL1 expression levels by using microRNAs (miRNAs) was assessed.

methodsDLL1 mRNA and protein expression levels were measured in three different neuroblastoma cell lines using quantitative real-time PCR and Western Blot analysis, respectively. Activation of the Notch pathway as a result of increased levels of DLL1 was analyzed by Immunofluorescence and Western Blot methods. In silico tools revealed the possibility to act on DLL1 expression levels with miRNAs, in particular with the miRNA-34 family. Neuroblastoma cells were transfected with miRNA-34 family members, and the effect of miRNAs transfection on DLL1 mRNA expression levels, on cell differentiation, proliferation and apoptosis was measured.

resultsIn this study, the DLL1 ligand was identified as the Notch pathway component highly expressed in neuroblastoma cells with MYCN amplification. In silico analysis demonstrated that DLL1 is one of the targets of miRNA-34 family members that maps on chromosome regions that are frequently deregulated or deleted in neuroblastoma. We studied the possibility to use miRNAs to target DLL1. Among all miRNA-34 family members, miRNA-34b is able to significantly downregulate DLL1 mRNA expression levels, to arrest cell proliferation and to induce neuronal differentiation in malignant neuroblastoma cells.

conclusionsTargeted therapies have emerged as new strategies for cancer treatment. This study identified the Notch ligand DLL1 as a novel and attractive molecular target in childhood neuroblastoma and its results could help to devise a targeted therapy using miRNAs.

Indexed as

Molecular Targeted TherapyCalcium-Binding ProteinsCell DifferentiationCell Line, TumorCell ProliferationChildChild, PreschoolGene Expression Regulation, NeoplasticHumansIntercellular Signaling Peptides and ProteinsLigandsMembrane ProteinsMicroRNAsNeuroblastomaReceptors, NotchSignal TransductionCalcium-Binding ProteinsDLK1 protein, humanIntercellular Signaling Peptides and ProteinsLigandsMembrane ProteinsMicroRNAsMIRN34 microRNA, humanReceptors, NotchDelta-like 1miRNAsMolecular targetNeuroblastomaNotch pathway

Identifiers

PMID28525978
PMCPMC5438559
OpenAlexW2616491757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.